knowledge -WSS

knowledge

author：explore 2025-10-02 18:05:17 - browse：43732

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Medical students need to learn the potent medicine of empathy

focus

WSS

Boston competes with Raleigh

Pancreatic cancer early detection could be helped by AI

Zyn nicotine pouches become unlikely player in latest culture war

Louisiana bill approved classifying abortion pills as controlled substances

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Bernie Sanders is gearing up to subpoena pharma CEOs

entertainment

knowledge

hotspot

Affirmative action in medical school literally saved lives

Guardant Health colon cancer test endorsed by FDA advisory panel

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

DIEP, the 'gold standard' of breast reconstruction, is under threat

Reconstructing family trees of blood cells may help predict disease

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Virginia high school admissions case could be legal follow

Why Medicare shouldn’t cover every FDA

leisure time

Merck, Johnson & Johnson CEOs will testify on high drug prices

Clinicians often fail to acknowledge the pain caused by long Covid

Decentralized clinical trials need collaboration to achieve wider use

Bird flu makes raw milk dangerous to consume, mouse study finds

Why some fertility treatments produce more boy babies

Guardant Health colon cancer test endorsed by FDA advisory panel

focus

leisure time

entertainment

hotspot